医学
冲程(发动机)
缺血性中风
药理学
水肿
缺血
溶栓
下调和上调
皮质扩散性抑郁症
脑水肿
血脑屏障
麻醉
治疗效果
心脏病学
神经保护
缺氧(环境)
脑缺血
小胶质细胞
内科学
氢溴化物
髓腔
中枢神经系统
作者
Song Guo,An-Qing Li,Fan-Kai Chen,Ding-Zhou Weng,Zheng Wang,Chong Yang,Yujie Zhang,Yi Zhang,Xin Chang,Huaping Liang,Jian Liu
标识
DOI:10.1038/s41467-026-73995-0
摘要
Vasogenic cerebral edema is a severe complication of delayed thrombolysis for ischemic stroke, for which no pharmacological treatment exists. Anisodine hydrobromide (Ani), an alkaloid used clinically in China for vascular disorders, is investigated for its potential to mitigate this condition. Here we show that Ani treatment improves survival and neurological function in a mouse model of delayed rtPA-induced cerebral edema by preserving the integrity of the blood-brain barrier. Utilizing proteomics and microarray screening, we identify megakaryocyte-associated tyrosine kinase (Matk) as a direct target of Ani. We demonstrate that Ani binding stabilizes Matk, preventing its degradation and suppressing the activation of Src kinase. This inhibition consequently blocks the dual paracellular and transcellular leakage pathways that drive vasogenic edema. Our findings reveal the Matk-Src signaling axis as a therapeutic target and support Ani as a promising clinical candidate for preventing post-thrombolytic complications in stroke management. Ischemic stroke treatment can be complicated by brain edema if thrombolytic drugs are given too late. Here, the authors show that anisodine hydrobromide mitigates this dangerous edema in mice by targeting the Matk-Src pathway to protect blood vessels in the brain
科研通智能强力驱动
Strongly Powered by AbleSci AI